Chris is a founding partner of Green, Griffith & Borg-Breen LLP.  As a seasoned IP trial lawyer with over 30 years of experience in the life sciences, he concentrates his practice on pharmaceuticals, biologics, chemistry and medical devices.  As a Hatch-Waxman expert, Chris leverages his advocacy and technical skills to help clients shape successful litigation outcomes.  With a focus on litigation, he partners closely with his clients to provide strategic formulation, portfolio and pre-litigation counseling concerning IP and relevant FDA issues affecting 505(b)(1), 505(b)(2) and ANDA applications, as well as biologics (BPCIA).  With expertise gained by representing both brand and generic companies, he provides strategies and opinions directed toward attaining each client’s goals, whether this involves API and excipient selection, trade dress, formulation attributes, labeling or portfolio development, and then works with each client to execute the desired strategy – whether this involves litigation in the federal courts or other contested forums.

Chris and his team are also skilled in inter partes reviews (IPRs), reexaminations, reissues and post-grant proceedings before the PTAB.  He also has significant experience in navigating the 505(b)(2) pathway, including advising clients on PIV certification and Orange Book issues, related FDA issues, and patent portfolio development.  Due diligence is also a strength.  Chris is also a former adjunct law professor and taught a Master's level patent law course for many years.